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THE HEPATITIS C TREATMENT MARKET & PROJECTED REVENUES
Sofosbuvir’s estimated $80,000 USD price 
tag for a 12-week course makes it out of 
reach for nearly 90% of people living with 
hepatitis C worldwide who reside in low-  
and middle-income countries.
The hepatitis C treatment market is projected 
to reach over $15 billion USD through sales in 




    
 
n December 2013, authorities in the 
U.S. and Europe approved Gilead’s 
highly anticipated hepatitis C drug, 
sofosbuvir. This drug and other new 
treatments for hepatitis C, called direct- 
acting antivirals (DAAs), have created a 
buzz among medical and research com-
munities, patients, and financial analysts 
tracking the multi-billion dollar hepatitis C 
treatment market. Taken in pill form rather 
than by injection, and with cure rates and 
side effect profiles better than previously 
seen for hepatitis C, many are hailing 
sofosbuvir and other new oral medicines as 
“miracle cures.”
The new drugs, however, come with a 
major limitation—price. Business analysts 
currently estimate that Gilead could charge 
$80,000 USD for a single course of treat-
ment of sofosbuvir.[i] With nearly 90% of 
the estimated 185 million people living 
with hepatitis C worldwide residing in 
low- and middle-income countries,[ii] where 
government health budgets are small and 
where most patients have to pay for medi-
cines out of pocket, this price tag means 
that sofosbuvir and the other new 
hepatitis C medicines will remain out of 
reach for the majority of those in need. 
PEGYLATED INTERFERON
Termed the “viral time bomb” by the 
World Health Organization because 
most people living with hepatitis C are 
unaware of their status and can remain 
without symptoms for decades, hepa-
titis C infects three to four million new 
people per year.[iii] More than 350,000 
people die annually from hepatitis 
C-related liver diseases.[iii] Unlike HIV, 
however, hepatitis C—though also  
transmitted through contaminated 
blood—is curable.
For the past decade, the medicine  
pegylated interferon, or Peg-IFN, has 
been the backbone of hepatitis C treat-
ment. An injectable medication, Peg-IFN 
is far from ideal in terms of tolerability 
and ease of use, but cures a significant 
proportion of patients who use it in 
combination with another medicine,  
ribavirin. With a price tag of up to 
$20,000 USD per course, Peg-IFN  
has remained unaffordable, and  
inaccessible in most low- and middle-
income countries.[iv]
NEW AND IMPROVED TREATMENTS— 
AT WHAT COST?
Clinical trial data on the new hepatitis 
C medicines are very promising. Oral 
rather than injectable, they have cured 
patients with some strains (genotypes) 
of hepatitis C more rapidly, more  
efficaciously, and with fewer side effects 
when compared to PEG-IFN. For other  
patients, treatment still requires Peg-IFN, 
and the combination of this medicine 
with the new oral drugs also increases 
treatment efficacy, and reduces treat-
ment duration from up to 48 weeks to 
as little as 12. These advantages are all 
cause to celebrate—but only if patients 
can gain access to the new medicines. 
Sofosbuvir’s estimated $80,000 USD 
price tag for a 12-week course will be 
many times more than the current cost 
of Peg-IFN, and for many will be added 
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                           Reaching more by costing less HIV TREATMENT: 
In the case of access 
to HIV medicines,  
it was the entry  
of generic  
competitors into  
the market that 
drove massive price 
reductions
MIDDLE-INCOME COUNTRIES AND  
PHARMACEUTICAL PROFITS
The greatest burden of hepatitis C falls on 
middle-income countries, which account 
for nearly three-quarters of all those liv-
ing with hepatitis C.[ii] These countries are 
referred to as “emerging markets” by the 
pharmaceutical industry in anticipation of 
increasing numbers of citizens and govern-
ments purchasing brand name medicines 
over time. Current marketing approaches 
by the industry in these countries  
frequently target wealthy elites and their 
physicians, rather than seeking to increase 
sales to the population as a whole.
Profits for the manufacturers of hepatitis 
C drugs are expected to be enormous even 
if they sell no medicine in middle-income 
countries. The hepatitis C market is expect-
ed to reach over $15 billion USD by 2022 
from sales in Japan, five major European 
markets (France, Germany, Italy, Spain, UK), 
and the U.S. alone,[v] where fewer than five 
percent of those infected with hepatitis C 
reside. Sofosbuvir is expected to command 
the largest share of this market.[v]
LESSONS TO BE LEARNED FROM HIV 
The cost to manufacture a course of  
sofosbuvir is estimated to be only $68-136 
USD[vi]—a sharp contrast to the estimated 
$80,000 USD price tag—so steep price 
reductions are possible. The simplest 
solution would be for manufacturers of 
the new hepatitis C medicines to lower 
their prices to levels affordable for  
governments operating with limited 
health budgets in low-and middle-
income countries. Treatment advocates 
worldwide, including the humanitar-
ian aid organization, Doctors Without 
Borders, are already suggesting a 
target price of less than $500 USD.[vii]
Unfortunately, past experience with 
HIV suggests that drug companies are 
unlikely to voluntarily extend significant 
discounts to middle-income countries, 
even if they may be open to reducing 
the price for the world’s poorest.  
In the case of access to HIV medicines, 
it was the entry of generic competitors 
into the market that drove massive price 
reductions—lowering the price of antiret-
roviral treatment from over $10,000 
USD to under $100 USD per patient,  
per year.[viii] This competition, and the 
community activism that challenged a 
system where treatment was only for 
the rich, enabled the tremendous scale-
up of treatment in low-and middle-
income countries. Before the entry of 
generic medicines, only 50,000 people 
living with HIV in limited resource set-
tings were receiving HIV treatment.[ix] 
Today, nearly 10 million do.[x] 
The HIV example is instructive for how 
availability of hepatitis C medicines may 
also be expanded. Even where the new 
hepatitis C medicines are patented—
granting monopolies to manufacturers 
and blocking the entry of generics — 
international law permits governments 
to override such patents to protect 
public health, for instance through com-
pulsory licensing.[xi] In November 2013, 
the public interest legal group, Initiative 
for Medicines, Access and Knowledge 
(I-MAK), challenged Gilead’s sofosbuvir 
patent application in India, charging  
that the drug was not sufficiently  
innovative to merit patent protection, 
paving the way for generic manufactur-
ing of the medicine.[vii]
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PRICE REDUCTION IS POSSIBLE
Since the new hepatitis C drugs are unlikely to 
be available anytime soon in low- and middle- 
income countries, Peg-IFN will remain critical 
for those who need hepatitis C treatment 
now. Recent experiences with this medicine 
underscore that change in pricing is possible. 
A combination of civil society advocacy and 
government commitment has helped to lower 
the price of Peg-IFN in countries as varied as 
the Republic of Georgia, Thailand, Ukraine, and 
Egypt, with brand name medicines going from 
$18,000 USD for a 48-week course to as low 
as $2,000 USD.[iv]
A key question is whether citizens, govern-
ment officials, and international bodies like 
the World Health Organization feel committed 
to push for truly affordable medicine pricing 
that prioritizes people’s health over corporate 
profit. The new medicines may be promising 
from a clinical standpoint, but price reduction 
remains the key to ensuring scale-up, and to 
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A key question is 
whether citizens,  
government officials, 
and international  
bodies like the World 
Health Organization 
feel committed to 
push for truly  
affordable medicine 
pricing that  
prioritizes people’s 
health over  
corporate profit.
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